• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 2

Episode 2 - Immunotherapy in CRPC

Video

During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.

Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.

Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.


Related Videos
Tiffany Meng, PharmD, oncology pharmacist with UCSF Health
Rachel Rohaidy, MD
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Screenshot of an interview with Shaun McKenzie, MD
Jeffrey Stark, MD, vice president and head of medical immunology at UCB.
Sabarish Ayyappan, MD
Dr Maria DeYoreo
Screenshot of an interview with Shaun McKenzie, MD
Jade E. Jones, MD
Screenshot of an interview with Rohan Garje, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.